CRISPR Therapeutics will present Phase 1 clinical data for its investigational gene editing therapy, CTX310, targeting ANGPTL3 at the AHA Scientific Sessions 2025 on November 8, 2025. They will also present a poster on CTX340 for refractory hypertension. The Company’s portfolio includes CTX320, CTX340, and CTX450 for various diseases. CRISPR Therapeutics aims to create transformative gene-based medicines for cardiovascular, autoimmune, and rare diseases. The company has formed strategic partnerships to advance its research and development efforts. The presentation abstracts will be available on the AHA website and CRISPR Therapeutics’ website post-event. 1. The stock market experienced a sharp decline today, with the S&P 500 falling by 2.5% and the Dow Jones Industrial Average dropping by 600 points. Investors are concerned about rising inflation and the potential impact on interest rates.

2. The FDA has approved a new drug for the treatment of Alzheimer’s disease, marking the first new treatment for the condition in nearly 20 years. The drug, called Aduhelm, has shown promising results in clinical trials and is expected to be a game-changer for patients suffering from the disease.

3. In international news, tensions are rising between Israel and Hamas as violence escalates in the region. Israel has launched airstrikes on Gaza in response to rocket attacks from Hamas, leading to civilian casualties on both sides.

4. The CDC has announced that fully vaccinated individuals no longer need to wear masks or practice social distancing in most indoor and outdoor settings. This new guidance is a major step towards returning to pre-pandemic norms and has been met with both praise and criticism from the public.

Read more at 1. Apple unveils new iPhone 13 lineup with improved cameras, longer battery life, and faster processor. – Reuters
2. Tesla announces plans to build a new Gigafactory in Texas, creating thousands of jobs in the area. – CNBC
3. Amazon Prime Day sales break records, with over $10 billion in global sales during the two-day event. – Wall Street Journal
4. Pfizer reports positive results from final analysis of COVID-19 vaccine trial in children ages 5 to 11. – CBS MarketWatch
5. Facebook faces backlash over whistleblower’s claims of harmful practices and impact on mental health. – Barchart: CRISPR Therapeutics to Present Late-Breaking Data at the